Skip to content
Catalyst

4-(trimethylamino)butanoateWhat was measured

Measured, with no finding

71 endpoints

Show what was measuredHide what was measured
  • free fatty acid concentration in liver

    decreases

    In particular, the liver concentration of FFA in JVS mice was decreased to the wild-type control level, accompanied by significant decreases in long-chain fatty acids, palmitic acid and stearic acid

    PMID 11341370 · one of two readings recorded this

  • free fatty acid concentration in plasma

    no effect

    Although the plasma concentrations of FFA in both types of mice were unchanged after administration of gamma-butyrobetaine, the concentrations of palmitic acid and stearic acid were significantly decreased.

    PMID 11341370 · one of two readings recorded this

  • free fatty acid, long-chain fatty acid, palmitic acid and stearic acid concentrations in liver

    no effect

    whereas those in wild-type mice were not changed

    PMID 11341370 · one of two readings recorded this

  • L-carnitine concentration in brain

    increases

    levels in the brain, liver and kidney were also significantly increased

    PMID 11341370 · one of two readings recorded this

  • L-carnitine concentration in kidney

    increases

    levels in the brain, liver and kidney were also significantly increased

    PMID 11341370 · one of two readings recorded this

  • L-carnitine concentration in liver

    increases

    levels in the brain, liver and kidney were also significantly increased

    PMID 11341370 · one of two readings recorded this

  • L-carnitine concentration in plasma, brain, liver and kidney

    no effect

    whereas those in wild-type mice hardly changed

    PMID 11341370 · one of two readings recorded this

  • L-carnitine concentration in plasma

    increases

    After intravenous administration of gamma-butyrobetaine (50 mg kg(-1)), the concentration of L-carnitine in the plasma of JVS mice reached about twice that of the control level

    PMID 11341370 · one of two readings recorded this

  • liver free fatty acid concentration (total FFA, palmitic acid, stearic acid) and plasma and tissue L-carnitine concentration after intravenous gamma-butyrobetaine in juvenile visceral steatosis (JVS) mice

    decreases, liver FFA in JVS mice decreased to the wild-type control level

    Not recorded as a finding: this platform holds no node for the endpoint

    In particular, the liver concentration of FFA in JVS mice was decreased to the wild-type control level, accompanied by significant decreases in long-chain fatty acids, palmitic acid and stearic acid, whereas those in wild-type mice were not changed.

    PMID 11341370 · one of two readings recorded this

  • liver free fatty acid, palmitic acid and stearic acid concentration in JVS mice

    decreases, liver FFA in JVS mice decreased to the wild-type control level

    Not recorded as a finding: the only sentence reporting it does not name gamma-butyrobetaine (quote not self-supporting); no outcome node for liver free fatty acids

    In particular, the liver concentration of FFA in JVS mice was decreased to the wild-type control level, accompanied by significant decreases in long-chain fatty acids, palmitic acid and stearic acid, whereas those in wild-type mice were not changed.

    PMID 11341370 · one of two readings recorded this

  • long-chain fatty acid concentration in liver

    decreases

    In particular, the liver concentration of FFA in JVS mice was decreased to the wild-type control level, accompanied by significant decreases in long-chain fatty acids, palmitic acid and stearic acid

    PMID 11341370 · one of two readings recorded this

  • palmitic acid concentration in liver

    increases

    The concentrations of total free fatty acid (FFA), palmitic acid and stearic acid in the liver of JVS mice were significantly higher than those in wild-type mice.

    PMID 11341370 · one of two readings recorded this

  • palmitic acid concentration in liver

    decreases

    In particular, the liver concentration of FFA in JVS mice was decreased to the wild-type control level, accompanied by significant decreases in long-chain fatty acids, palmitic acid and stearic acid

    PMID 11341370 · one of two readings recorded this

  • palmitic acid concentration in plasma

    decreases

    Although the plasma concentrations of FFA in both types of mice were unchanged after administration of gamma-butyrobetaine, the concentrations of palmitic acid and stearic acid were significantly decreased.

    PMID 11341370 · one of two readings recorded this

  • stearic acid concentration in liver

    increases

    The concentrations of total free fatty acid (FFA), palmitic acid and stearic acid in the liver of JVS mice were significantly higher than those in wild-type mice.

    PMID 11341370 · one of two readings recorded this

  • stearic acid concentration in liver

    decreases

    In particular, the liver concentration of FFA in JVS mice was decreased to the wild-type control level, accompanied by significant decreases in long-chain fatty acids, palmitic acid and stearic acid

    PMID 11341370 · one of two readings recorded this

  • stearic acid concentration in plasma

    decreases

    Although the plasma concentrations of FFA in both types of mice were unchanged after administration of gamma-butyrobetaine, the concentrations of palmitic acid and stearic acid were significantly decreased.

    PMID 11341370 · one of two readings recorded this

  • total free fatty acid concentration in liver

    increases

    The concentrations of total free fatty acid (FFA), palmitic acid and stearic acid in the liver of JVS mice were significantly higher than those in wild-type mice.

    PMID 11341370 · one of two readings recorded this

  • inducible nitric oxide synthase inhibition in vitro

    no effect

    Neither mildronate nor gamma-butyrobetaine could inhibit the inducible nitric oxide synthase in vitro.

    PMID 14725614 · one of two readings recorded this

  • inducible nitric oxide synthase inhibition in vitro

    no effect

    Neither mildronate nor gamma-butyrobetaine could inhibit the inducible nitric oxide synthase in vitro.

    PMID 14725614 · one of two readings recorded this

  • nitric oxide concentration in all studied tissues

    decreases

    Its natural analogue gamma-butyrobetaine (30 mg/kg) triggered a twofold decrease of the nitric oxide concentration in all studied tissues 30 min. after the administration.

    PMID 14725614 · one of two readings recorded this

  • nitric oxide concentration in all studied tissues

    no effect

    Nitric oxide reached the initial level 2 hr later.

    PMID 14725614 · one of two readings recorded this

  • nitric oxide level in blood

    increases

    in blood from 33.6+/-12.4 to 638+/-136 ng/g tissue

    PMID 14725614 · one of two readings recorded this

  • nitric oxide level in brain cortex and cerebellum

    decreases

    Administration of the antiischaemic drug, mildronate (120 mg/kg) caused a significant twofold decrease of the nitric oxide level in brain cortex and cerebellum 1 hr after drug administration.

    PMID 14725614 · one of two readings recorded this

  • nitric oxide level in brain cortex

    increases

    in brain cortex from 46.0+/-3.4 to 227+/-27 ng/g tissue

    PMID 14725614 · one of two readings recorded this

  • nitric oxide level in cerebellum

    increases

    in cerebellum from 27.7+/-2.6 to 218+/-30 ng/g tissue

    PMID 14725614 · one of two readings recorded this

  • nitric oxide level in heart

    increases

    in heart from 4.8+/-0.7 to 271+/-26 ng/g tissue

    PMID 14725614 · one of two readings recorded this

  • nitric oxide level in kidney

    increases

    in kidney from 3.3+/-0.5 to 356+/-31 ng/g tissue

    PMID 14725614 · one of two readings recorded this

  • nitric oxide level in liver

    increases

    the nitric oxide level in liver of lipopolysaccharide-treated rats increased from 27.6+/-4.7 to 1485+/-129 ng/g tissue

    PMID 14725614 · one of two readings recorded this

  • nitric oxide level in testes

    increases

    in testes from 13.8+/-1.1 to 86+/-8 ng/g tissue

    PMID 14725614 · one of two readings recorded this

  • tissue nitric oxide level (liver, heart, blood, kidney, brain cortex, cerebellum, testes), electron paramagnetic resonance, in lipopolysaccharide-treated rats

    decreases, twofold decrease in all studied tissues 30 min after administration

    Not recorded as a finding: no outcome node for tissue nitric oxide concentration; recorded in the mechanism lane as depletes nitric oxide instead

    Its natural analogue gamma-butyrobetaine (30 mg/kg) triggered a twofold decrease of the nitric oxide concentration in all studied tissues 30 min. after the administration.

    PMID 14725614 · one of two readings recorded this

  • distribution of radioactivity as L-carnitine in plasma and tissues (tracer dose)

    no effect

    In an experiment with tracer dose of the compounds, 12 h following administration of [3H]butyrobetaine plasma and tissues contained radioactivity exclusively in L-carnitine and in similar amounts as in the other group of animals receiving L-[3H]carnitine.

    PMID 2036448 · one of two readings recorded this

  • increment in L-carnitine in kidney

    increases

    kidney, 1227 nmol/g vs. 652 nmol/g

    PMID 2036448 · one of two readings recorded this

  • increment in L-carnitine in liver

    increases

    liver, 469 nmol/g vs. 258 nmol/g

    PMID 2036448 · one of two readings recorded this

  • increment in L-carnitine in muscle

    increases

    muscle, 1043 nmol/g vs. 881 nmol/g

    PMID 2036448 · one of two readings recorded this

  • increment in L-carnitine in plasma

    increases

    plasma, 79.4 nmol/ml vs. 39.3 nmol/ml

    PMID 2036448 · one of two readings recorded this

  • increment in L-carnitine (loading dose)

    no effect

    Butyrobetaine (100 mumol) caused similar increments when it was administered intraperitoneally.

    PMID 2036448 · one of two readings recorded this

  • increment in L-carnitine (loading dose)

    no effect

    12 h later it was found that butyrobetaine caused the same increments in L-carnitine as L-carnitine administration

    PMID 2036448 · one of two readings recorded this

  • L-carnitine increments in kidney, liver, muscle (nmol/g) and plasma (nmol/ml) 12 h after oral [3H]butyrobetaine versus L-[3H]carnitine in rats

    kidney 1227 vs 652 nmol/g; liver 469 vs 258 nmol/g; muscle 1043 vs 881 nmol/g; plasma 79.4 vs 39.3 nmol/ml

    Not recorded as a finding: no outcome node for tissue L-carnitine concentration; the comparator is L-carnitine (active), not absence of the compound

    The increments in the organs of the butyrobetaine-treated group (in decreasing order) were as follows: kidney, 1227 nmol/g vs. 652 nmol/g; liver, 469 nmol/g vs. 258 nmol/g; muscle, 1043 nmol/g vs. 881 nmol/g; plasma, 79.4 nmol/ml vs. 39.3 nmol/ml.

    PMID 2036448 · one of two readings recorded this

  • L-carnitine levels in all tissues after a single dose

    increases

    This work shows that butyrobetaine administered to rats in a single dose can be highly effective in elevating L-carnitine levels in all tissues.

    PMID 2036448 · one of two readings recorded this

  • carnitine after deoxycarnitine administration (matrix not stated, by context urine)

    increases

    Not recorded as a finding: no outcome node; not recorded as converted_to because the paper attributes the change to tissue exchange between L-carnitine and deoxycarnitine, not conversion

    Conversely, administration of deoxycarnitine caused an increase of carnitine.

    PMID 2804068 · one of two readings recorded this

  • carnitine

    increases

    Conversely, administration of deoxycarnitine caused an increase of carnitine.

    PMID 2804068 · one of two readings recorded this

  • deoxycarnitine concentration in kidney

    decreases

    Administration of D-carnitine to rats previously loaded with deoxycarnitine significantly depleted the elevated deoxycarnitine concentration in skeletal muscle and kidney while increasing it in plasma.

    PMID 2804068 · one of two readings recorded this

  • deoxycarnitine concentration in plasma

    increases

    Administration of D-carnitine to rats previously loaded with deoxycarnitine significantly depleted the elevated deoxycarnitine concentration in skeletal muscle and kidney while increasing it in plasma.

    PMID 2804068 · one of two readings recorded this

  • deoxycarnitine concentration in skeletal muscle

    decreases

    Administration of D-carnitine to rats previously loaded with deoxycarnitine significantly depleted the elevated deoxycarnitine concentration in skeletal muscle and kidney while increasing it in plasma.

    PMID 2804068 · one of two readings recorded this

  • deoxycarnitine in urine

    increases

    Administration of L-carnitine to rats was followed by an increase of deoxycarnitine in urine.

    PMID 2804068 · one of two readings recorded this

  • L-carnitine concentration in heart, skeletal muscle, kidney, liver and plasma after deoxycarnitine administration

    decreases, transient but significant diminution of L-carnitine in heart, skeletal muscle and kidney, but not in liver and plasma

    Not recorded as a finding: the sentence reporting it says 'The latter treatment' and never names deoxycarnitine (quote not self-supporting); no outcome node for tissue L-carnitine

    The latter treatment also produced a transient but significant diminution of L-carnitine in heart, skeletal muscle and kidney, but not in liver and plasma.

    PMID 2804068 · one of two readings recorded this

  • L-carnitine concentration in heart, skeletal muscle, kidney, liver and plasma, and carnitine in urine, after deoxycarnitine administration to rats

    decreases, transient but significant diminution of L-carnitine in heart, skeletal muscle and kidney, not in liver and plasma

    Not recorded as a finding: the supporting sentence never names the compound

    The latter treatment also produced a transient but significant diminution of L-carnitine in heart, skeletal muscle and kidney, but not in liver and plasma.

    PMID 2804068 · one of two readings recorded this

  • L-carnitine in heart

    decreases

    The latter treatment also produced a transient but significant diminution of L-carnitine in heart, skeletal muscle and kidney, but not in liver and plasma.

    PMID 2804068 · one of two readings recorded this

  • L-carnitine in kidney

    decreases

    The latter treatment also produced a transient but significant diminution of L-carnitine in heart, skeletal muscle and kidney, but not in liver and plasma.

    PMID 2804068 · one of two readings recorded this

  • L-carnitine in liver

    no effect

    The latter treatment also produced a transient but significant diminution of L-carnitine in heart, skeletal muscle and kidney, but not in liver and plasma.

    PMID 2804068 · one of two readings recorded this

  • L-carnitine in plasma

    no effect

    The latter treatment also produced a transient but significant diminution of L-carnitine in heart, skeletal muscle and kidney, but not in liver and plasma.

    PMID 2804068 · one of two readings recorded this

  • L-carnitine in skeletal muscle

    decreases

    The latter treatment also produced a transient but significant diminution of L-carnitine in heart, skeletal muscle and kidney, but not in liver and plasma.

    PMID 2804068 · one of two readings recorded this

  • carnitine biosynthesis from epsilon-N-trimethyl-L-lysine in vivo, and serum and tissue L-carnitine concentrations, in weanling rats fed 1% dietary gamma-butyrobetaine for 32 days

    decreases

    Not recorded as a finding: this platform holds no node for the endpoint

    Dietary L-carnitine, D-carnitine and gamma-butyrobetaine (1%) reduced carnitine biosynthesis from epsilon-N-trimethyl-L-lysine in vivo.

    PMID 6619971 · one of two readings recorded this

  • carnitine biosynthesis from epsilon-N-trimethyl-L-lysine in vivo in rats fed 1% dietary gamma-butyrobetaine for 32 days; also serum and tissue L-carnitine concentrations

    decreases

    Not recorded as a finding: this platform holds no node for the endpoint

    Dietary L-carnitine, D-carnitine and gamma-butyrobetaine (1%) reduced carnitine biosynthesis from epsilon-N-trimethyl-L-lysine in vivo.

    PMID 6619971 · one of two readings recorded this

  • carnitine biosynthesis from epsilon-N-trimethyl-L-lysine in vivo

    decreases

    Dietary L-carnitine, D-carnitine and gamma-butyrobetaine (1%) reduced carnitine biosynthesis from epsilon-N-trimethyl-L-lysine in vivo.

    PMID 6619971 · one of two readings recorded this

  • carnitine biosynthesis from epsilon-N-trimethyl-L-lysine in vivo

    decreases

    Dietary L-carnitine, D-carnitine and gamma-butyrobetaine (1%) reduced carnitine biosynthesis from epsilon-N-trimethyl-L-lysine in vivo.

    PMID 6619971 · one of two readings recorded this

  • carnitine biosynthesis from epsilon-N-trimethyl-L-lysine in vivo

    decreases

    Dietary L-carnitine, D-carnitine and gamma-butyrobetaine (1%) reduced carnitine biosynthesis from epsilon-N-trimethyl-L-lysine in vivo.

    PMID 6619971 · one of two readings recorded this

  • L-carnitine concentration in all tissues studied

    increases

    Rats fed diets supplemented with L-carnitine (0.1-1.0%) had increased L-carnitine concentrations in serum and all tissues studied.

    PMID 6619971 · one of two readings recorded this

  • L-carnitine concentration in heart

    decreases

    D-Carnitine (1% of diet) significantly reduced serum and heart L-carnitine concentrations from control levels, and the effects of gamma-butyrobetaine depended on the level of dietary supplementation.

    PMID 6619971 · one of two readings recorded this

  • L-carnitine concentration in serum and tissues

    modulates

    the effects of gamma-butyrobetaine depended on the level of dietary supplementation

    PMID 6619971 · one of two readings recorded this

  • L-carnitine concentration in serum

    decreases

    D-Carnitine (1% of diet) significantly reduced serum and heart L-carnitine concentrations from control levels, and the effects of gamma-butyrobetaine depended on the level of dietary supplementation.

    PMID 6619971 · one of two readings recorded this

  • L-carnitine concentration in serum

    increases

    Rats fed diets supplemented with L-carnitine (0.1-1.0%) had increased L-carnitine concentrations in serum and all tissues studied.

    PMID 6619971 · one of two readings recorded this

  • mean L-carnitine concentration in serum and tissues (except liver)

    increases

    Mean L-carnitine concentrations in serum and tissues (except liver) from rats fed equivalent amounts of L-carnitine, as the racemic mixture DL-carnitine, were greater than controls but were consistently lower than in rats fed L-carnitine alone.

    PMID 6619971 · one of two readings recorded this

  • mean L-carnitine concentration in serum and tissues (except liver)

    decreases

    Mean L-carnitine concentrations in serum and tissues (except liver) from rats fed equivalent amounts of L-carnitine, as the racemic mixture DL-carnitine, were greater than controls but were consistently lower than in rats fed L-carnitine alone.

    PMID 6619971 · one of two readings recorded this

  • toxic effects

    no effect

    Other than mild diarrhea with high levels of some supplements, no toxic effects of these compounds were observed under the conditions employed and within the time frame of the study.

    PMID 6619971 · one of two readings recorded this

  • rate of carnitine biosynthesis (estimated from carnitine excretion)

    increases

    Ascorbate-supplemented, ascorbate-deficient, and pair-fed (to ascorbate-deficient) animals showed an increase in the rate of carnitine biosynthesis (as estimated from measured rates of carnitine excretion) of 32 to 40 mumol.kg body weight-1.d-1 following supplementation with epsilon-N-trimethyllysine

    PMID 7752911 · one of two readings recorded this

  • rate of carnitine biosynthesis (estimated from carnitine excretion)

    increases

    Likewise, animals in each experimental group showed an increase in the rate of carnitine biosynthesis of 41 to 50 mumol.kg body weight-1.d-1 after supplementation with gamma-butyrobetaine.

    PMID 7752911 · one of two readings recorded this

  • rate of free and total carnitine excretion

    no effect

    For guinea pigs not given a carnitine precursor supplement, rates of free and total carnitine excretion for ascorbate-deficient (but not pair-fed) animals were threefold higher than for ascorbate-supplemented animals during days 19 to 28 of the feeding regimen.

    PMID 7752911 · one of two readings recorded this

  • rate of free carnitine excretion

    increases

    For guinea pigs not given a carnitine precursor supplement, rates of free and total carnitine excretion for ascorbate-deficient (but not pair-fed) animals were threefold higher than for ascorbate-supplemented animals during days 19 to 28 of the feeding regimen.

    PMID 7752911 · one of two readings recorded this

  • rate of total carnitine excretion

    increases

    For guinea pigs not given a carnitine precursor supplement, rates of free and total carnitine excretion for ascorbate-deficient (but not pair-fed) animals were threefold higher than for ascorbate-supplemented animals during days 19 to 28 of the feeding regimen.

    PMID 7752911 · one of two readings recorded this